Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases

Biomaterials

Volumn 37, Issue , 2015, Pages 367-382

  Bartneck, Matthias ^a   Scheyda, Katharina M ^a   Warzecha, Klaudia T ^a   Rizzo, Larissa Y ^a   Hittatiya, Kanishka ^b   Luedde, Tom ^a   Storm, Gert ^c,d   Trautwein, Christian ^a   Lammers, Twan ^a,c,d   Tacke, Frank ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Dexamethasone; Liposomes; Liver fibrosis; Liver injury; Macrophages; T cells

Indexed keywords

CELL DEATH; DISEASES; MACROPHAGES; T-CELLS;

ANTI-INFLAMMATORIES; DEXAMETHASONES; EXPERIMENTAL MODELS; FLUORESCENT CELLS; LIVER FIBROSIS; LIVER INJURIES; MECHANISM OF ACTION; THERAPEUTIC POTENTIALS;

LIPOSOMES;

DEXAMETHASONE SODIUM PHOSPHATE; FLUORESCENT DYE; LIPOSOME; DEXAMETHASONE;

ACUTE HEPATITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; BLOOD; CELL POLARITY; CHRONIC HEPATITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; EXPERIMENTAL HEPATITIS; EXPERIMENTAL LIVER FIBROSIS; EXPERIMENTAL LIVER INJURY; FLUORESCENCE IMAGING; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KUPFFER CELL; LIPOSOMAL DELIVERY; LIVER; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CELL DEATH; CELL SURVIVAL; COMPLICATION; DRUG EFFECTS; FLUORESCENCE; HEPATITIS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER CIRRHOSIS; LIVER DISEASES; PATHOLOGY; TISSUE DISTRIBUTION;

MUS;

ANIMALS; CELL DEATH; CELL SURVIVAL; DEXAMETHASONE; FLUORESCENCE; HEPATITIS; IMMUNOMODULATION; IMMUNOSUPPRESSION; INFLAMMATION; LIPOSOMES; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; MICE, INBRED C57BL; ORGAN SPECIFICITY; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 84922323024     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.10.030     Document Type: Article

References (34)

1. Goram A.L., Richmond P.L. Pegylated liposomal doxorubicin: tolerability and toxicity. Pharmacotherapy 2001, 21:751-763.
2. Crielaard B.J., Lammers T., Schiffelers R.M., Storm G. Drug targeting systems for inflammatory disease: one for all, all for one. JControl Release 2012, 161:225-234.
3. Kawarabayashi N., Seki S., Hatsuse K., Kinoshita M., Takigawa T., Tsujimoto H., et al. Immunosuppression in the livers of mice with obstructive jaundice participates in their susceptibility to bacterial infection and tumor metastasis. Shock 2010, 33:500-506.
4. Bartneck M., Peters F.M., Warzecha K.T., Bienert M., van Bloois L., Trautwein C., et al. Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages. Nanomedicine 2014, 10:1209-1220.
5. Karkhanis J., Verna E.C., Chang M.S., Stravitz R.T., Schilsky M., Lee W.M., et al. Steroid use in acute liver failure. Hepatology 2014, 59:612-621.
6. Nguyen-Khac E., Thevenot T., Piquet M.A., Benferhat S., Goria O., Chatelain D., et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. NEngl J Med 2011, 365:1781-1789.
7. Longmire M., Choyke P.L., Kobayashi H. Dendrimer-based contrast agents for molecular imaging. Curr Top Med Chem 2008, 8:1180-1186.
8. Poelstra K., Prakash J., Beljaars L. Drug targeting to the diseased liver. JControl Release 2012, 161:188-197.
9. Tacke F., Zimmermann H.W. Macrophage heterogeneity in liver injury and fibrosis. JHepatol 2014, 60:1090-1096.
10. Sadauskas E., Wallin H., Stoltenberg M., Vogel U., Doering P., Larsen A., et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol 2007, 4:10.
11. Bartneck M., Ritz T., Keul H.A., Wambach M., Bornemann J., Gbureck U., et al. Peptide-functionalized gold nanorods increase liver injury in hepatitis. ACS Nano 2012, 6:8767-8777.
12. Xue J., Schmidt S.V., Sander J., Draffehn A., Krebs W., Quester I., et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 2014, 40:274-288.
13. Raes G., Van den Bergh R., De Baetselier P., Ghassabeh G.H., Scotton C., Locati M., et al. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. JImmunol 2005, 174:6561. author reply -2.
14. Zimmermann H.W., Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 2011, 10:509-536.
15. Herbert D.R., Holscher C., Mohrs M., Arendse B., Schwegmann A., Radwanska M., et al. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 2004, 20:623-635.
16. Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985, 812:55-65.
17. Fiske C.H., Subbarow Y. The colorimetric determination of phosphorus. JBiol Chem 1925, 66:375-400.
18. Rouser G., Fkeischer S., Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970, 5:494-496.
19. Bartneck M., Keul H.A., Singh S., Czaja K., Bornemann J., Bockstaller M., et al. Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry. ACS Nano 2010, 4:3073-3086.
20. Baeck C., Wehr A., Karlmark K.R., Heymann F., Vucur M., Gassler N., et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012, 61:416-426.
21. Melgert B.N., Olinga P., Van Der Laan J.M., Weert B., Cho J., Schuppan D., et al. Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology 2001, 34:719-728.
22. Fichter M., Baier G., Dedters M., Pretsch L., Pietrzak-Nguyen A., Landfester K., et al. Nanocapsules generated out of a polymeric dexamethasone shell suppress the inflammatory response of liver macrophages. Nanomedicine 2013, 9:1223-1234.
23. Benameur H., Latour N., Schandene L., Van Vooren J.P., Flamion B., Legros F.J. Liposome-incorporated dexamethasone palmitate inhibits in-vitro lymphocyte response to mitogen. JPharm Pharmacol 1995, 47:812-817.
24. Schweingruber N., Haine A., Tiede K., Karabinskaya A., van den Brandt J., Wust S., et al. Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. JImmunol 2011, 187:4310-4318.
25. Liedtke C., Luedde T., Sauerbruch T., Scholten D., Streetz K., Tacke F., et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 2013, 6:19.
26. Tacke F., Luedde T., Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009, 36:4-12.
27. Strassburg C.P. Autoimmune hepatitis. Dig Dis 2013, 31(1):155-163.
28. Wang H.X., Liu M., Weng S.Y., Li J.J., Xie C., He H.L., et al. Immune mechanisms of concanavalin A model of autoimmune hepatitis. World J Gastroenterol WJG 2012, 18:119-125.
29. Karlmark K.R., Weiskirchen R., Zimmermann H.W., Gassler N., Ginhoux F., Weber C., et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50:261-274.
30. Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Zfur Gastroenterol 2007, 45:63-70.
31. Stahn C., Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008, 4:525-533.
32. Herold M.J., Reichardt H.M. Glucocorticoid-induced apoptosis in animal models of multiple sclerosis. Crit Rev Immunol 2013, 33:183-202.
33. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. Anovel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. JImmunol Methods 1995, 184:39-51.
34. Ozbakir B., Crielaard B.J., Metselaar J.M., Storm G., Lammers T. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. JControl Release 2014, 190:624-636.